Time and diffusion lesion size in major anterior circulation ischemic strokes

Stroke

Volumn 45, Issue 10, 2014, Pages 2936-2941

  Hakimelahi, Reza ^a   Vachha, Behroze A ^a   Copen, William A ^a   Papini, Giacomo D E ^a   He, Julian ^a   Higazi, Mahmoud M ^a   Lev, Michael H ^a   Schaefer, Pamela W ^a   Yoo, Albert J ^a   Schwamm, Lee H ^a   González, R Gilberto ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

brain infarction; diffusion; magnetic resonance imaging; stroke

Indexed keywords

AGED; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PERFUSION; CIRCULATION; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; MAJOR ANTERIOR CIRCULATION ISCHEMIC STROKE; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCINTIGRAPHY; STROKE PATIENT; BRAIN; BRAIN ANGIOGRAPHY; BRAIN CIRCULATION; CEREBROVASCULAR ACCIDENT; COLLATERAL CIRCULATION; COMPUTER ASSISTED DIAGNOSIS; DISEASE COURSE; PATHOLOGY; PHYSIOLOGY; TIME; VASCULARIZATION;

AGED; BRAIN; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR CIRCULATION; COLLATERAL CIRCULATION; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; STROKE; TIME FACTORS;

EID: 84922480928     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005644     Document Type: Article

References (34)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. González RG, Furie KL, Goldmacher GV, Smith WS, Kamalian S, Payabvash S, et al. Good outcome rate of 35% in IV-tPA-treated patients with computed tomography angiography confirmed severe anterior circulation occlusive stroke. Stroke. 2013;44:3109-3113.
3. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
4. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
5. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.
6. Saver JL. Time is brain-quantified. Stroke. 2006;37:263-266.
7. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
8. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
9. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
10. Khatri P, Abruzzo T, Yeatts SD, Nichols C, Broderick JP, Tomsick TA; IMS I and II Investigators. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009;73:1066-1072.
11. González RG. Imaging-guided acute ischemic stroke therapy: From "time is brain" to "physiology is brain". AJNR Am J Neuroradiol. 2006;27:728-735.
12. Bang OY, Saver JL, Buck BH, Alger JR, Starkman S, Ovbiagele B, et al; UCLA Collateral Investigators. Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2008;79:625-629.
13. Christoforidis GA, Mohammad Y, Kehagias D, Avutu B, Slivka AP. Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol. 2005;26:1789-1797.
14. Liebeskind DS. Collaterals in acute stroke: beyond the clot. Neuroimaging Clin N Am. 2005;15:553-73, x.
15. Abou-Chebl A. Endovascular treatment of acute ischemic stroke may be safely performed with no time window limit in appropriately selected patients. Stroke. 2010;41:1996-2000.
16. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
17. Bardutzky J, Shen Q, Bouley J, Sotak CH, Duong TQ, Fisher M. Perfusion and diffusion imaging in acute focal cerebral ischemia: temporal vs. spatial resolution. Brain Res. 2005;1043:155-162.
18. Neumann-Haefelin T, Kastrup A, de Crespigny A, Yenari MA, Ringer T, Sun GH, et al. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. Stroke. 2000;31:1965-1972, discussion 1972.
19. Copen WA, Rezai Gharai L, Barak ER, Schwamm LH, Wu O, Kamalian S, et al. Existence of the diffusion-perfusion mismatch within 24 hours after onset of acute stroke: dependence on proximal arterial occlusion. Radiology. 2009;250:878-886.
20. Hakimelahi R, Yoo AJ, He J, Schwamm LH, Lev MH, Schaefer PW, et al. Rapid identification of a major diffusion/perfusion mismatch in distal internal carotid artery or middle cerebral artery ischemic stroke. BMC Neurol. 2012;12:132.
21. González RG, Hakimelahi R, Schaefer PW, Roccatagliata L, Sorensen AG, Singhal AB. Stability of large diffusion/perfusion mismatch in anterior circulation strokes for 4 or more hours. BMC Neurol. 2010;10:13.
22. Yoo AJ, Chaudhry ZA, Nogueira RG, Lev MH, Schaefer PW, Schwamm LH, et al. Infarct volume is a pivotal biomarker after intra-arterial stroke therapy. Stroke. 2012;43:1323-1330.
23. Yoo AJ, Verduzco LA, Schaefer PW, Hirsch JA, Rabinov JD, González RG. MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization. Stroke. 2009;40:2046-2054.
24. Sanák D, Nosál' V, Horák D, Bártková A, Zelenák K, Herzig R, et al. Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis. Neuroradiology. 2006;48:632-639.
25. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, et al; DEFUSE 2 study investigators. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): A prospective cohort study. Lancet Neurol. 2012;11:860-867.
26. Bang OY, Saver JL, Alger JR, Starkman S, Ovbiagele B, Liebeskind DS; UCLA Collateral Investigators. Determinants of the distribution and severity of hypoperfusion in patients with ischemic stroke. Neurology. 2008;71:1804-1811.
27. Nicoli F, Lafaye de Micheaux P, Girard N. Perfusion-weighted imagingderived collateral flow index is a predictor of MCA M1 recanalization after i. v. thrombolysis. AJNR Am J Neuroradiol. 2013;34:107-114.
28. Olivot JM, Mlynash M, Inoue M, Marks MP, Wheeler HM, Kemp S, et al; DEFUSE 2 Investigators. Hypoperfusion intensity ratio predicts infarct progression and functional outcome in the DEFUSE 2 Cohort. Stroke. 2014;45:1018-1023.
29. Mlynash M, Lansberg MG, De Silva DA, Lee J, Christensen S, Straka M, et al; DEFUSE-EPITHET Investigators. Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke. 2011;42:1270-1275.
30. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
31. Cocho D, Belvís R, Martí-Fàbregas J, Molina-Porcel L, Díaz-Manera J, Aleu A, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. 2005;64:719-720.
32. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA. 2000;283:1151-1158.
33. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924-928.
34. Nogueira RG, Smith WS, Sung G, Duckwiler G, Walker G, Roberts R, et al; MERCI and Multi MERCI Writing Committee. Effect of time to reperfusion on clinical outcome of anterior circulation strokes treated with thrombectomy: pooled analysis of the MERCI and Multi MERCI trials. Stroke. 2011;42:3144-3149.